Can Fite Biopharma Ltd
TASE:CANF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Unifin Financiera SAB de CV
BMV:UNIFINA
|
MX |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (9.6), the stock would be worth ₪-52 782.05 (11 688% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.1 | ₪455.5 |
0%
|
| Industry Average | 9.6 | ₪-52 782.05 |
-11 688%
|
| Country Average | 12.7 | ₪-70 018.49 |
-15 472%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| IL |
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
19.3m ILS | -0.1 | -0.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 14.2 | 85 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 12.1 | 19.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 21.1 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 12.9 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR | 41 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 10.5 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.2 |
| Median | 12.7 |
| 70th Percentile | 21.8 |
| Max | 361.2 |
Other Multiples
Can Fite Biopharma Ltd
Glance View
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
